California’s ambitious plan to manufacture its own low-cost insulin, a lifeline for millions of diabetics, has hit a significant roadblock.
California’s ambitious plan to manufacture its own low-cost insulin, a lifeline for millions of diabetics, has hit a significant roadblock.
In